NEW YORK, October 3, 2016 /PRNewswire/ --
IDEA Pharma, the leading Path to Market Design practice in pharma/ biotech, is delighted to announce the appointment of Mhairi Strachan as Principal, to the NYC practice.
With over 16 years of strategic and operational oncology experience, Mhairi brings to IDEA a wealth of knowledge across successful launches, in line growth brands and early development products. She also brings a fitting creative energy that has been key to her unique success in the industry.
Mhairi's most recognizable success is the leadership, rigor, and creativity she showed as the Worldwide Brand Team Lead for OPDIVO at BMS - leading to what is recognized as one of the most successful launches of an oncology asset in history. In addition, her experience includes Global Brand Lead for XALKORI at Pfizer, and Global Brand Director, Oncology for SPRYCEL at BMS, and was a key team member on many of BMS's other heavy hitter oncology brands. Notably, she also brings a depth of experience in co RX/DX biomarker launches across several assets.
"We are delighted that Mhairi has joined IDEA Pharma. She brings with her deep experience of commercializing oncology assets, including some of the most pivotal advances of recent years in targeted therapeutics and immuno-oncology. Her skills and knowledge will allow IDEA Pharma to further develop capability in assisting our clients with developing innovative path-to-market strategies for their oncology assets," comments Alexander Gray, IDEA's Chief Medical Officer.
"Oncology is exploding with possibilities, and that means it is no longer business as usual…," added Mike Rea, CEO. "I couldn't be more proud that a rockstar with proven ability to lead differentiated launches in oncology is joining IDEA, with a mission to continue to change things positively. We've already been involved with path to market design for 7 of the top 10 projected oncology products by 2020 - I know Mhairi and we will look to improve on that success, to make sure meaningful medicines continue to reach patients."
Notes to Editors:
About IDEA Pharma:
Through knowledge, insight and uncommon creativity, we unlock the potential of every molecule, inspiring and empowering the pharma industry to deliver medicines that make a difference. We work with clients early in the lifecycle at proof of concept, crafting a compelling product story and building a world-class strategy that helps every molecule reach its potential. It's what we do best. And there's nobody that does it quite like us.
Past Accomplishments Include:
Path to Market Design for 7 of the top 10 (projected) oncology products by 2020 // Positioned 3 of 11 products Reuters called 2015 Blockbusters, including the Top 2 // Path to Market Design for 5 NMEs that were FDA approved in 2015
For more information, please contact Jess Spataro: [email protected] T: +1-212-929-7953 http://www.ideapharma.com
SOURCE IDEA Pharma
Advertisement
IDEA Pharma, the leading Path to Market Design practice in pharma/ biotech, is delighted to announce the appointment of Mhairi Strachan as Principal, to the NYC practice.
Advertisement
With over 16 years of strategic and operational oncology experience, Mhairi brings to IDEA a wealth of knowledge across successful launches, in line growth brands and early development products. She also brings a fitting creative energy that has been key to her unique success in the industry.
Mhairi's most recognizable success is the leadership, rigor, and creativity she showed as the Worldwide Brand Team Lead for OPDIVO at BMS - leading to what is recognized as one of the most successful launches of an oncology asset in history. In addition, her experience includes Global Brand Lead for XALKORI at Pfizer, and Global Brand Director, Oncology for SPRYCEL at BMS, and was a key team member on many of BMS's other heavy hitter oncology brands. Notably, she also brings a depth of experience in co RX/DX biomarker launches across several assets.
"We are delighted that Mhairi has joined IDEA Pharma. She brings with her deep experience of commercializing oncology assets, including some of the most pivotal advances of recent years in targeted therapeutics and immuno-oncology. Her skills and knowledge will allow IDEA Pharma to further develop capability in assisting our clients with developing innovative path-to-market strategies for their oncology assets," comments Alexander Gray, IDEA's Chief Medical Officer.
"Oncology is exploding with possibilities, and that means it is no longer business as usual…," added Mike Rea, CEO. "I couldn't be more proud that a rockstar with proven ability to lead differentiated launches in oncology is joining IDEA, with a mission to continue to change things positively. We've already been involved with path to market design for 7 of the top 10 projected oncology products by 2020 - I know Mhairi and we will look to improve on that success, to make sure meaningful medicines continue to reach patients."
Notes to Editors:
About IDEA Pharma:
Through knowledge, insight and uncommon creativity, we unlock the potential of every molecule, inspiring and empowering the pharma industry to deliver medicines that make a difference. We work with clients early in the lifecycle at proof of concept, crafting a compelling product story and building a world-class strategy that helps every molecule reach its potential. It's what we do best. And there's nobody that does it quite like us.
Past Accomplishments Include:
Path to Market Design for 7 of the top 10 (projected) oncology products by 2020 // Positioned 3 of 11 products Reuters called 2015 Blockbusters, including the Top 2 // Path to Market Design for 5 NMEs that were FDA approved in 2015
For more information, please contact Jess Spataro: [email protected] T: +1-212-929-7953 http://www.ideapharma.com
SOURCE IDEA Pharma
